125459 -

: This guideline is a cornerstone for developers of Advanced Therapy Medicinal Products (ATMPs) in the European Union.

: Characterizing potential immune responses to the viral vector or the new protein produced by the therapy.

: Checking if the patient might "shed" or spread the virus/vector through secretions. 125459

: Evaluating whether the viral vector or therapeutic gene could unintentionally be passed on to future generations.

The guideline, officially titled , provides a framework for non-clinical studies required before a gene therapy can be used in human clinical trials. Guide to EMA Guideline 125459 : This guideline is a cornerstone for developers

The number most commonly refers to a specific scientific guideline established by the European Medicines Agency (EMA) regarding the development of Gene Therapy Medicinal Products (GTMPs) .

: Determining where the therapeutic gene goes in the body and how long it persists in both target and non-target cells. : Evaluating whether the viral vector or therapeutic

For more detailed technical specifications, you can access the full Guideline on Non-Clinical Studies for GTMPs via the official .